Outcomes after Chronic Blood Transfusion in Thalassemia with Pulmonary Arterial Hypertensio

Phase 4

Suspended

• Conditions: Thalassemia patients; Thalassemia; pulmonary arterial hypertension; blood transfusion

• Registration Number: TCTR20110000019
• Lead Sponsor: Faculty of Medicine Chiang Mai University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10-14
• Study Completion: 2012-10-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Suspended
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Thalassemia intermedia: E/β-thalassaemia
Pulmonary arterial hypertension (PAP > 35 mmHg by ECHO)
Hemoglobin level 6.0 – 9.9 g/dl.
Serum ferritin level less than 2,000 ug/dl.
Capable of follow up and Informed concent

Exclusion Criteria

clinical evidence of other secondary causes of pulmonary arterial hypertension, eg. HIV infection, collagen vascular diseases, chronic obstructive airway disease, acquired heart disease associated with pulmonary venous hypertension eg. mitral valve disease, congenital heart disease and hyperthyroidism.
- Poor compliance of chelation therapy.
- The patients who had alloantibody to red blood cells.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary artery pressure difference (PASP) initial, 6 months, 12 months Echocardiography: The differences of PASP between before and the end of study

Secondary Outcome Measures

Name	Time	Method
Six minutes walk test (6MWT) differences initial, 6 months, 12 months Six minutes walk test (6MWT)